Aytu biopharma reports fiscal 2025 second quarter operational and financial results

Net income of $0.8 million adjusted ebitda1 of $1.3 million pediatric portfolio net revenue up 86% sequentially first quarterly sequential prescription increase for both adhd and pediatric portfolios since q2 fiscal 2023 $20.4 million cash balance at december 31, 2024 company to host conference call and webcast today, february 12, 2025, at 4:30 p.m. eastern time denver, co / access newswire / february 12, 2025 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 second quarter.
AYTU Ratings Summary
AYTU Quant Ranking